Clinical trial
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the…
NCT00025233 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00025233 |
|---|---|
| Title | Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix |
| Official title | A Phase II Trial of Bevacizumab (rhuMAB VEGF) (NSC #704865) in the Treatment of Persistent and Recurrent Squamous Cell Carcinoma of the Cervix (Group A) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer |
| Intervention type | Biological, Other |
| Interventions | bevacizumab, laboratory biomarker analysis |
| Enrollment | 50 |
| Start date | Apr 1, 2002 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 24, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: